Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Presant

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Cancer Research|February 1, 1979
Imidoester inhibition of lymphocyte DNA synthesisC A Presant, S Parker
Cancer|October 1, 1977
Severe myelosuppression from piperazinedione, (NSC No. 135758), cyclophosphamide plus dimethyl-triazeno-imidazole carboxamide (DTIC)C A Presant, C Klahr
Medical and Pediatric Oncology|January 1, 1983
Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovaryC A Presant, A Bartolucci
Cancer|September 1, 1978
Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myelomaC A Presant, C Klahr
The Journal of Biological Chemistry|April 10, 1976
Surface alterations in calf lymphocytes oxidized by sodium periodateC A Presant, S Parker
Clinical and Experimental Immunology|January 1, 1977
Enhanced DNA synthesis in isolated calf lymph node lymphocyte culturesC A Presant, S Parker
Cancer|May 15, 1982
Prognostic factors in metastatic malignant melanoma: The Southeastern Cancer Study Group ExperienceC A Presant, A A Bartolucci
Medical and Pediatric Oncology|January 1, 1984
Phase II evaluation of chlorozotocin in metastatic sarcomasC A Presant, A A Bartolucci
American Journal of Clinical Oncology|April 1, 1982
Phase II trial of piperazinedione in metastatic sarcomaC A Presant, A A Bartolucci
Cancer|January 1, 1980
Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinomaC A Presant, S Hillinger, C Klahr
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Cancer Research|February 1, 1979
Imidoester inhibition of lymphocyte DNA synthesisC A Presant, S Parker
Cancer|October 1, 1977
Severe myelosuppression from piperazinedione, (NSC No. 135758), cyclophosphamide plus dimethyl-triazeno-imidazole carboxamide (DTIC)C A Presant, C Klahr
Medical and Pediatric Oncology|January 1, 1983
Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovaryC A Presant, A Bartolucci
Cancer|September 1, 1978
Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myelomaC A Presant, C Klahr
The Journal of Biological Chemistry|April 10, 1976
Surface alterations in calf lymphocytes oxidized by sodium periodateC A Presant, S Parker
Clinical and Experimental Immunology|January 1, 1977
Enhanced DNA synthesis in isolated calf lymph node lymphocyte culturesC A Presant, S Parker
Cancer|May 15, 1982
Prognostic factors in metastatic malignant melanoma: The Southeastern Cancer Study Group ExperienceC A Presant, A A Bartolucci
Medical and Pediatric Oncology|January 1, 1984
Phase II evaluation of chlorozotocin in metastatic sarcomasC A Presant, A A Bartolucci
American Journal of Clinical Oncology|April 1, 1982
Phase II trial of piperazinedione in metastatic sarcomaC A Presant, A A Bartolucci
Cancer|January 1, 1980
Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinomaC A Presant, S Hillinger, C Klahr
Pageof 7